In November 1935 at Lisbon’s Santa Marta Hospital, Portuguese neurologist António Egas Moniz drilled into the skulls of his first twenty psychiatric patients, severing the white-matter tracts of the frontal lobes, and reported — on the basis of a few weeks of observation and no controls — that he had cured or improved most of them; the gap between that claim and the documented reality is the entire case. The reality was a procedure that, in its American form, lobotomized roughly 40,000 to 50,000 people, blunted or destroyed the personalities of a large fraction of them, killed on the order of one in twenty, and was performed most heavily on women, the institutionalized, children, and the powerless who could not consent. It was not validated against a sham, not measured against an inert comparator, not followed over the years it would have taken to see what it did; it was launched on the authority of a respected clinician working fast in a field that had nothing else to offer overcrowded asylums.
The operation did not fail quietly in a backwater. It was crowned. Moniz received the 1949 Nobel Prize in Physiology or Medicine “for his discovery of the therapeutic value of leucotomy in certain psychoses,” the only Nobel ever awarded for a surgical destruction of healthy brain tissue. That prize functioned as a regulatory and reputational green light: it converted an undertested operation into a respectable standard of care and supercharged its American evangelist, neurologist Walter Jackson Freeman II, who by the late 1960s had performed or supervised more than 3,500 lobotomies — a death toll among his own patients estimated at roughly 490.
Freeman’s signature innovation was to remove the operating room entirely. His “transorbital” or “ice-pick” lobotomy, first performed on a living patient on January 17, 1946, drove a leucotome through the thin bone of the eye socket and swept it across the frontal lobes, often in under ten minutes, frequently with no surgeon present and no general anaesthetic — he stunned patients with electroshock instead. He performed it on minors, on patients with headaches and depression, and on Rosemary Kennedy in 1941, who was left permanently incapacitated. The surrogate endpoint — a calmer, more “manageable” ward patient — was achieved. The actual endpoint — a recovered human being — usually was not.
The reckoning came not from a tribunal but from a molecule. Chlorpromazine, synthesized in 1950 and shown to control psychosis by 1952, offered the same institutional benefit — quieter, more tractable patients — without drilling through the skull. Within roughly a decade the lobotomy collapsed from a Nobel-honored frontier therapy to a byword for medical hubris. It was never recalled, never banned by a single statute; it was simply abandoned, made obsolete by a pill, and is now the textbook case of how prestige, a flattering surrogate measure, and an absence of controlled evidence can scale a mutilating procedure to tens of thousands before anyone is required to prove it works.
In 1957 surgeon J. Roderick Kitchell and colleagues at Presbyterian Hospital in Philadelphia, following an Italian lead, began tying off the internal mammary arteries in the chests of angina patients and reporting that roughly two-thirds felt better — and the gap between that reported relief and the operation’s actual physiological effect is the entire case, because the operation did almost nothing the body could measure. The procedure was supposed to relieve the crushing chest pain of coronary disease by occluding the internal mammary arteries so that blood would be diverted into the heart muscle. It was simple, it was fast, it was performed under local anaesthetic, and within two or three years it had been carried out on thousands of patients across Italy and the United States on the strength of uncontrolled before-and-after testimonials.
The reported numbers looked persuasive: in the largest case series, on the order of two-thirds to three-quarters of patients said their angina improved, many dramatically, with effects holding up over months and years of follow-up. What no one had done was ask whether the cut, rather than the ligature, was doing the work. Angina is a subjective, fluctuating symptom, and the act of being operated on by a confident surgeon is among the most powerful placebos in medicine.
The reckoning was unusually clean and unusually fast. Between 1959 and 1960 two small randomized trials — Leonard A. Cobb’s group at the University of Washington and E. Grey Dimond’s at the University of Kansas — did something no surgical evaluation had done before: they randomized angina patients to either the real ligation or a sham operation, an identical skin incision in which the arteries were exposed but left intact, with neither the patient nor the assessing physician knowing which had been done. The sham patients improved exactly as much as the ligated ones. The exercise electrocardiograms were unchanged by either operation. The benefit was real to the patients and entirely placebo in origin.
The operation was abandoned almost immediately — not banned by any agency, not litigated, but disproven and quietly dropped. Its lasting legacy is the opposite of its intended one: internal mammary artery ligation is now the founding textbook example of why surgery, like a drug, must be tested against a placebo, and of how a self-limiting subjective symptom plus an enthusiastic operator can manufacture thousands of “cures” out of nothing but expectation and a scar.
In 1894, Johns Hopkins surgeon William Stewart Halsted published the results of his “complete operation” for breast cancer — an en-bloc amputation of the breast, both pectoral muscles, and the axillary lymph nodes — and reported that it had cut local recurrence from the 51–82% rates of his European contemporaries to a fraction of that; the gap between that local-control victory and the survival it never delivered is the entire case. The radical mastectomy controlled the wound bed and was mistaken, for three-quarters of a century, for a control of the disease. It was performed on the order of nine in ten American women with breast cancer well into the 1970s, left them with a hollowed chest wall, a frozen shoulder, and near-ubiquitous arm lymphedema, and — as randomized trials would eventually show — bought not one additional day of survival over far lesser surgery.
The operation did not fail because it was crude. It was, by the standards of 1894, a genuine advance: Halsted’s en-bloc dissection and his obsession with surgical technique made him one of the founders of modern American surgery, and the early survival figures — a five-year survival roughly double that of untreated women — were real. The error was theoretical. Halsted built the operation on an anatomical hypothesis: that breast cancer spread in an orderly, centrifugal, contiguous fashion outward from the breast through the lymphatics, so that cutting wider and deeper must, by geometry, cut ahead of the disease. If the theory were true, more radical surgery would mean more cures. The theory was false.
Cancer that had spread had usually spread through the bloodstream before the surgeon ever arrived, and cancer that had not spread was cured by far less. The radical mastectomy’s mutilating margins therefore changed the scar without changing the outcome. Critics — Geoffrey Keynes in England, George “Barney” Crile Jr. at the Cleveland Clinic — argued this from the 1930s and 1950s and were dismissed by a surgical establishment that treated the Halsted operation as settled doctrine.
The reckoning came from a randomized trial run by a surgeon who had once performed the operation himself. Bernard Fisher’s NSABP Protocol B-04, begun in 1971, randomized 1,665 women among radical mastectomy and two lesser procedures; B-06, begun in 1976, added lumpectomy. At every follow-up out to 25 years, survival was statistically identical. The Halsted hypothesis of contiguous spread was replaced by the systemic-disease model — that breast cancer is, at diagnosis, often already a whole-body problem the scalpel cannot outrun. The radical mastectomy was not banned; it was abandoned, retired by evidence as the textbook case of a mutilating operation sustained for 75 years by an elegant theory that happened to be wrong.
In 1933 the Austrian psychiatrist Manfred Sakel announced from Vienna that he could break schizophrenia by injecting patients with enough insulin to crash their blood sugar into deep coma — and reported, on uncontrolled case series with no comparison group, recovery rates of 70 to 80 percent; the distance between that claim and what a controlled trial eventually found is the whole of this case. The procedure that resulted held patients in repeated, deliberately induced hypoglycemic comas — typically a course of 20 to 60 sessions, each lasting up to an hour, terminated by glucose — across asylums in Europe and North America for two decades, and killed on the order of one to two patients in every hundred treated, with some series running higher.
Insulin coma therapy (ICT) did not survive on evidence. It survived on enthusiasm and on a flattering selection effect. As the British psychiatrist Harold Bourne argued in his 1953 Lancet paper “The Insulin Myth,” ICT units selected younger, recently-ill, better-prognosis patients, lavished them with intensive nursing in dedicated wards, and then credited insulin for an improvement that the selection and the attention had largely produced. Bourne’s verdict — that insulin patients were “an elite group sharing common privileges and perils,” and that the coma added nothing specific — was a theoretical demolition that the field initially refused to print; the Journal of Mental Science sat on his manuscript for a year and rejected it, telling him to “get more experience.”
The empirical reckoning arrived in 1957, when Brian Ackner, Arthur Harris and A.J. Oldham published in The Lancet one of the first randomized controlled trials in psychiatric history. Fifty schizophrenia patients were randomly allocated either to insulin coma or to an identical regimen in which the unconsciousness was produced by barbiturates instead — same ward, same nursing, same coma, different agent. There was no difference in outcome. Whatever the regimen achieved, insulin was not the active ingredient. Within a few years ICT had collapsed, helped over the edge by chlorpromazine, which by the late 1950s delivered comparable results without driving anyone into a coma. It was never recalled and never banned; it was simply discredited and abandoned, and it is now taught as the first major therapy retired by a randomized controlled trial — and a textbook illustration of how a selection effect can masquerade as a cure.
The regimen that German obstetricians Bernhardt Krönig and Carl Joseph Gauss perfected at the Freiburg women’s clinic from 1906, and that an American feminist crusade exported to U.S. hospitals from June 1914, promised “painless childbirth” — and the entire case lives in the fact that it never delivered painlessness at all. The injection of scopolamine and morphine did not abolish the agony of labor; it abolished the patient’s memory of it. Women still felt every contraction and still screamed and thrashed through them; scopolamine merely erased the recollection afterward, so that a mother who had been strapped to a padded “crib” bed for hours, blindfolded and plugged with cotton, woke believing she had slept through a miracle. The surrogate endpoint — a patient who reported no memory of pain — was achieved. The actual endpoint — a labor that was safe and painless — was not.
The harms were two-fold and physical. The mothers, delirious from scopolamine, became so disoriented and combative that obstetricians routinely restrained them with leather straps to a screened crib-bed, gauze over the eyes and wadding in the ears, so they could not injure themselves during the thrashing the drug induced. The newborns, whose blood took up the morphine that freely crossed the placenta, were born sedated — flaccid, cyanotic, with depressed reflexes and suppressed breathing, exposed to asphyxia and sometimes requiring resuscitation that early-twentieth-century obstetrics could not reliably provide.
What carried Twilight Sleep was not obstetric data but a consumer movement. A June 1914 McClure’s Magazine article, “Painless Childbirth,” by Marguerite Tracy and Constance Leupp, triggered thousands of letters; Manhattan suffragists founded the National Twilight Sleep Association that year and campaigned through the New York Times, the Ladies’ Home Journal, and lecture halls, framing the right to forget labor as a feminist demand. The reckoning was equally a matter of public sentiment. In August 1915 one of the movement’s own leading advocates, Mrs. Frances X. Carmody of Brooklyn, died of hemorrhage delivering her third child under Twilight Sleep at Long Island College Hospital; her physician and husband insisted the drugs were blameless, but the symbol was lethal to the cause, and demand collapsed within roughly fifteen months.
No statute banned it. The combination simply could not be administered safely outside the quiet, individualized, heavily-staffed Freiburg setting, and once safer regional and inhalational analgesia matured, the regimen was abandoned as a relic — a textbook case of an intervention validated by the memory of the patient rather than by her safety or her child’s.